- RedHill Biopharma Ltd RDHL announced the publication of positive data from a Phase 2 study RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.
- The study showed that RHB-107 met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and a 100% reduction in hospitalization due to COVID-19.
- Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.
- Data showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm.
- The study also showed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm reporting new severe COVID-19 symptoms.
- Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. eight days with placebo.
- Price Action: RDHL shares are up 27.2% at $0.18 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.